Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development
VANCOUVER, BC – May 4, 2023 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), today announced that it has entered into a CAD$1.2 million definitive supply agreement with a private entity focused on developing
May 4, 2023
